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Gastric cellof the pro-inﬂammatory cytokine Interleukin 6 (IL-6) have been reported to be
increased in Helicobacter pylori-infected subjects and, in gastric adenocarcinomas, the up-regulation of
intestinal mucin genes (MUC2 and MUC4) has been detected. To analyse the regulatory effects of IL-6 on the
activation of intestinal mucins, six gastric cancer cell lines were treated for different times with several
concentrations of IL-6, and the expression of MUC2 and MUC4 was evaluated. IL-6 induced MUC4 expression,
detected by quantitative RT-PCR, Western blot and immunoﬂuorescence, and MUC2 expression was not
affected. MUC4 mRNA levels decreased after blocking the gp130/STAT3 pathway at the level of the receptor,
and at the level of STAT3 activation using the AG490 speciﬁc inhibitor. MUC4 presents two putative binding
sites for STAT factors that may regulate MUC4 transcription after a pro-inﬂammatory stimulus as IL-6. By
EMSA, ChIP and site-directed mutagenesis we show that STAT3 binds to a cis-element at −123/−115, that
conveys IL-6 mediated up-regulation of MUC4 transcriptional activity. We also demonstrated that p-STAT3
binds to MUC4 promoter and a three-fold increase in p-STAT3 binding was observed after treating GP220
cells with IL-6.
In conclusion, IL-6 treatment induced MUC4 expression through the gp130/STAT3 pathway, indicating
the direct role of IL-6 on the activation of the intestinal mucin gene MUC4 in gastric cancer cells.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Gastric cancer is the fourth most common cancer worldwide and,
approximately, 90% of gastric cancers are adenocarcinomas [1]. Chronic
gastritis represents the ﬁrst step of the carcinogenetic process and it is
usually associated to the colonisation of the gastric mucosa by Helico-
bacter pylori (H. pylori) [2]. The inﬂammatory response to H. pylori
includes the release of pro-inﬂammatory cytokines such as interleukin
6 (IL-6), which levels have been described to be increased in the gastric
mucosa of H. pylori-infected subjects [3,4]. IL-6 belongs to a family of
cytokines including interleukin-11 (IL-11), leukaemia inhibitory factor
(LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNFT), cardio-
trophin-1 (CT-1), cardiotrophin-like cytokine (CLC) and interleukin-27
(IL-27), that can activate target genes involved in differentiation,
survival, apoptosis and proliferation [5]. These cytokines act as ligands
for the signalling receptor subunit gp130. IL-6 and IL-11 signal via gp130
homodimers, and signal transduction is mediated by the JAK/STAT
pathway, in particular STAT3 and to a minor extent STAT1 [5]. Tyrosine
phosphorylation is essential for STAT3 dimerization and its nuclear
translocation, where the STAT3 DNA-binding domain interacts with
STAT-binding sites in target gene promoters [6].34 933 160 410.
l rights reserved.Multiple sequential changes take place in the gastric mucosa
previously to the development of a gastric adenocarcinoma, such as
the loss of its characteristic mucin expression pattern (MUC5AC in the
superﬁcial epithelium and MUC6 in the glands [7,8]) and the
activation of intestinal mucin genes, MUC2 and MUC4, which are
detected in gastric tumors and in early events of the carcinogenesis
process, as intestinal metaplasia [9,10].
MUC4 is a membrane-bound mucin ﬁrstly cloned from a tracheo-
bronchial library [11]. It is composed by two subunits: the mucin
subunit MUC4α, and the transmembrane subunit MUC4β, that has
been reported to be ligand for ErbB2 via EGF-like domains, providing a
role for MUC4 in tumor progression [12,13]. MUC4, which is mainly
expressed in normal colon tissue, is up-regulated in some pre-
malignant lesions as well as in different types of tumors. In pancreatic
cancer, MUC4 is overexpressed [14] and, in a recent report using a
pancreatic adenocarcinoma cell line and an orthotopic mouse model,
MUC4 has been described to potentiate pancreatic tumor cell
proliferation, survival and invasion as well as changes in tumor cell–
extracellular matrix interactions and altered expression of growth-
and metastasis-associated genes [15]. The activation of MUC4 expres-
sion has been also shown in the dysplastic cervical process [16] and,
recently, we have described increased levels of MUC4 expression in
endometrial hyperplasia and endometrial carcinoma [17]. In most of
gastric tumorsMUC4 is also up-regulated, and can be detected at early
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information about the regulatory mechanisms involved in its activa-
tion has been reported in gastric cancer cells.
In the present study we have analysed the induction of MUC4
expression by IL-6 in gastric cancer cell lines and we demonstrate that
MUC4 activation occurs through gp130/STAT3 pathway.Fig. 1. IL-6 induces the expression of MUC4 in gastric cancer cell lines. (A) Quantitative RT-PC
MKN45, NUGC-4, St2957, St3051 and St23132 cells. Results are presented as the averages±S
course of MUC4 induction by IL-6 treatment in GP220 and MKN45 cells. The levels of M
experiments are shown.2. Materials and methods
2.1. Reagents and antibodies
IL-6 was purchased from PreproTech EC (London, UK) and Dubelcco's modiﬁed
Eagle's medium (DMEM) from Invitrogen (Carlsbad, CA). The speciﬁc inhibitor of STAT3
activation AG490 was obtained from Calbiochem (Darmstadt, Germany). Anti-human
gp130 receptor (CD130) antibody was purchased from Biosource (Camarillo, CA), andR analysis of MUC4 mRNA levels after 20 ng/ml and 40 ng/ml IL-6 treatment in GP220,
.D. (error bars) from two independent experiments. (B) Dose–response assay and time-
UC4 mRNA were detected by quantitative RT-PCR. Means±S.D. of two independent
Fig. 2.MUC4 protein expression induced by IL-6 treatment. (A) GP220 cells were treated with IL-6 (20 ng/ml and 40 ng/ml) for 20 h. Levels of MUC4 proteinwere detected byWestern
blot. KatoIII and St2957 cells were used as a positive and negative control respectively. β-actin (45 kDa) was used as a loading control. (B) Immunoﬂuorescent detection of MUC4.
GP220 control (untreated) cells do not express MUC4, that was detected after 40 ng/ml IL-6 treatment for 20 or 40 h.
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(Danvers, MA). For MUC4 detection rabbit polyclonal anti-MUC4 [10] was used. Anti-
mouse or anti-rabbit HRP conjugated antibodies were purchased from Dako Cytoma-
tion (Glostrup, DK), and for ﬂuorescent analysis anti-mouse Alexa Fluor 488 (Molecular
Probes, Leiden, The Netherlands) and anti-rabbit Cy2 (Jackson ImmunoResearch,
Cambridgeshire, UK) were used.
2.2. Cell culture and treatments
MKN45, KatoIII and NUGC-4 human gastric cancer cell lines were obtained from
ATCC. St2957, St3051, St23132 were characterised in Dr. Peter Vollmers' laboratory [18],
and GP220 cells were established in Dr Sobrinho-Simões' laboratory [19]. All cell lines
were maintained at 37 °C in CO2 atmosphere in 10% FCS supplemented DMEM. For IL-6
treatments semi conﬂuent cells were rinsed in phosphate-buffered saline (PBS) and
incubated for 2, 5, 10 or 20 h with 20 ng/ml or 40 ng/ml IL-6 diluted in DMEM.
For gp130 blocking experiments, cells were incubated with the mouse anti-human
gp130 antibody at 5 μg/ml concentration in DMEM for 3 h and then treated with IL-6 at
40 ng/ml for 20 h or at 20 ng/ml for 2 h.Fig. 3. IL-6 does not modulate MUC2 expression in GP220, MKN45, NUGC-4, St2957, St3051 a
RT-PCR after 20 ng/ml and 40 ng/ml IL-6 treatment for 20 h. Duplicates for each treatmentSTAT3 phosphorylation was prevented by incubating GP220 cells with 60 μM
AG490 in DMEM and cells were incubated with 40 ng/ml IL-6 for 2 or 5 h.
All treatments were performed in duplicate and three independent experiments
were done.
2.3. Quantitative reverse-transcription polymerase chain reaction analysis
Total RNA extraction was carried out from control and IL-6 stimulated cells using
GenEluteMammalianTotal RNAMiniprep kit (Sigma-Aldrich, St. Louis.MO). After rDNAse
I (Ambion, Austin, TX) treatment, quantitative determination of MUC4 mRNA levels was
performed in quatriplicate by using QuantiTect SYBR green reverse-transcription-PCR
(Qiagen GmbH, Germany). MUC4was ampliﬁed by primers 5′-CTTACT CTGGCC AAC TCT
GTA GTG-3′ (sense) and 5′-GAG AAG TTG GGC TTG ACT GTC-3′. (antisense) [20].
Hypoxanthine-guanine phosphoribosyl transferase (HPRT) mRNA (GeneCards database,
NCBI36:X) was analysed as an internal control by using oligonucleotides 5′-GGCCA-
GACTTTGTTGGATTTG-3′ (sense) and 5′-TGCGCTCATCTTAGGCTTTGT-3′ (antisense). RT-
PCR and data collection were performed on the ABI Prism 7900HT system. All
quantiﬁcations were normalized to the endogenous control (HPRT).nd St23132 gastric cancer cells. MUC2 mRNA levels were analysed by semi-quantitative
are shown. St2957 cells were used as a positive control in all the experiments.
1731R. Mejías-Luque et al. / Biochimica et Biophysica Acta 1783 (2008) 1728–17362.4. Semi-quantitative reverse-transcription polymerase chain reaction
MUC2 was ampliﬁed by primers 5′-CTT CGA CGG ACT CTA CTA CAG C-3′ (sense)
and 5′-CTT TGG TGT TGT TGC CAA AC-3′ (antisense) [20]. As a control for mRNA levels
β-actin cDNA was also ampliﬁed [21].
Ampliﬁcation conditions for MUC2 were: 94 °C 1′, 58 °C 30″ and 72 °C 30″ for
35 cycles. The size of the products was 387 bp for MUC2 and 349 bp for β-actin.
2.5. Immunoﬂuorescence
Cells were grown on glass coverslips. Semi conﬂuent untreated or 40 ng/ml IL-6
treated cells were ﬁxed in 4% PFA. After washing, cells were incubated with 50 mM
ammonium chloride for 30 min. Non-speciﬁc binding sites were blocked using 1/20
horse serum in PBS containing 1% bovine serum albumin (BSA). Cells were incubated
with anti-MUC4 antibody [10] for 90 min. After several washes, Cy2 anti-rabbit
antibody was incubated for 40 min. Nuclei were stained with propidium iodide. After
rinsing, coverslips were mounted in an aqueous mounting medium and observed in an
Olympus BX61 microscope.
2.6. Flow cytometry
GP220 and MKN45 cultured cells were treated with 40 ng/ml IL-6 for 20 h. 5×105
viable cells were incubated for 30 min at 4 °C with 1 μg/μl anti-gp130 antibody diluted
in PBS-1% BSA. Cells were rinsed in PBS-1% BSA and incubated with the secondary anti-
mouse Alexa Fluor 488 antibody for 30 min at 4 °C. After washing, ﬂuorescent analysis
was performed by using a FACScan (Becton Dickinson, Franklin Lakes, USA).
2.7. Cell lysates and Western blot analysis
Cytoplasmic cell lysates were obtained for gp130 and MUC4 detection by lysing the
cells in 50 mM Tris pH8, 62.5 mM EDTA and 1% Triton X-100 lysis buffer. For STAT3 and
p-STAT3 detection, total cellular pellets were solubilized in 2X SDS gel sample buffer
(20 mM dithiothreitol, 6% SDS, 0.25 M Tris pH 6.8, 10% glycerol, and bromophenyl blue)
and sonicated using 3–4 bursts of 5 s each. Extracts were boiled at 100 °C for 5 min and
immediately cooled on ice.
For MUC4 detection, Western blot was performed on 2% SDS-agarose gels as
previously described [22]. Anti-MUC4 antibody [10] was incubated for 2 h and bound
secondary antibody was detected using the ECL Western Blotting Substrate (Pierce,
Rockford, IL).
For gp130, STAT3 and p-STAT3 detection, lysates were electrophoresed on 8% SDS-
polyacrylamide gels. Separated proteins were blotted onto nitrocellulose membranes
(Protran, Dassel, Germany), blocked for 1 h at RT, and incubated overnight with the
speciﬁc primary antibodies following the manufacturer's instructions. ECL Western
Blotting Substrate, for gp130 and STAT3, or Supersignal West Femto, for p-STAT3, were
used.
2.8. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were obtained from IL-6 treated (20 ng/ml for 2 h) and untreated
GP220 cells. Pellets from cultured cells were resuspended in nuclear extraction buffer 1
(10 mM Hepes pH 7.6, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.5% NP-40 and
phosphatases and proteases inhibitors) and centrifuged. Pelleted nuclei were
resuspended in nuclear extraction buffer 2 (20 mM Hepes 7.6, 1.5 mM MgCl2,
840 mM KCl, 0.5 mM DTT, 0.2 mM EDTA, 25% glycerol and phosphatases and proteases
inhibitors). Supernatants obtained after centrifugation were dialyzed (20 mM Hepes
7.6, 100 mM KCl, 0.5 mM DTT, 0.2 mM EDTA, and 20% glycerol) for 5 h and the protein
content was measured by Bio-Rad Protein Assay.
30 μg of protein was incubated with the radiolabeled probes in incubation buffer
(10 mMHepes 7.9, 1 mM EDTA, 5 mMMgCl2, 10% glycerol, 0.5 mMDTT, 1 mg/ml BSA and
1 μg PolydI·dC (Amersham Biosciences, Piscataway, NJ) for 1 h on ice. The radiolabeled
probes used were: T51: 5′-TCTTCCCCATTCTTCCCAGCAGCCCAA-3′, and T63: 5′-
CCTGGCCCCTTCGGAGAAACGCA-3′, corresponding to the MUC4 promoter regions (NCBI
sequence, accession number AF241535 [23]) 3287–3313 and 3582–3604, respectively.
Unlabeled cold oligonucleotides, mutated T51 (5′-CTTCCCCATTCAGAGTTCCAGCC-3′) or
mutated T63 (5′-CTGGCCCCGCAGGATGGACGCA-3′) probes were used for competition
experiments (100x and 300x the concentration of the labeled probe). For supershift
assays, extracts were incubated with anti-p-STAT3 antibody or with irrelevant
immunoglobulins for 15 additional minutes. Samples were run on a 6% acrylamide gel.
Gels were dried and subjected to autoradiography.
2.9. Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation assay was performed as described [24]. Brieﬂy,
IL-6 treated (20 ng/ml IL-6 for 2 h) and untreated GP220 cells were cross-linked
with 1% formaldehyde, lysed and sonicated. After pre-clearing the chromatin with
protein A-agarose and irrelevant IgGs, p-STAT3 was immunoprecipitated by
incubating with the speciﬁc antibody overnight at 4 °C. Blocked agarose was
added to the samples and incubated for 2 h at 4 °C. Immunoprecipitates were
washed, eluted with elution buffer (0.1 M Na2CO3 and 1% SDS) and digested with K
proteinase for 30 min at RT and 30 min at 55 °C. 5 M NaCl was added to the
samples and they were incubated overnight at 65 °C. DNA puriﬁcation wasperformed using GFX PCR DNA and Gel Band Puriﬁcation Kit (GE Healthcare,
Buckinghamshire, UK).
Quantitative PCR was performed using two different sets of primers: Primer set 1:
5′-TCA TAC AGC CCC AAG GTC GC-3′ (sense), 5′-TAG CCG GGT TCC TGG GTC C-3′
(antisense), corresponding to the MUC4 promoter region 3251–3373 (NCBI sequence,
accession number AF241535 [23]) and Primer set 2: 5′-GAA AAG GGT GAT TAG CGT GG-
3′ (sense) and 5′-TCC CCT CAG GCG GCT GGC C-3′ (antisense), corresponding to the
3528–3632 region of MUC4 promoter. As internal control primers for the exon 1 of the
RNA polymerase 2were used. The sequences were: 5′-ACT CCAGGC TAGAGG GTC AC-3′
(sense) and 5′-CCG CAA GCT CAC AGG TGC TTT GCA GTT CC-3′ (antisense).
Quantiﬁcations were also normalized to input and calculated as a percentage of the
input.
2.10. Site-directed mutagenesis
Quick Change site-directed mutagenesis kit (Stratagene, La Jolla, CA) was used to
generate site-speciﬁc mutations in the STAT-binding site (T63) present in the MUC4
promoter construct 2150 [23]. Mutagenesis was performed as described [25]. The
oligonucleotide containing the desired mutations was designed according to the
manufacturer's instructions (mutated nucleotides are underlined and italicized): T63
(3008): CCCTGGCCCCTTAGCGTAAACGCACTTGG.
2.11. Luciferase reporter assays
Reporter assays were carried out in GP220 cells by using 400 ng of the humanwild
type MUC4 promoter construct 2150 (−1187/−1) [23], 400 ng of the mutated 2150
construct (3008) or 400 ng of pGL3 basic vector (Promega, Madison, WI). Cells were
cotransfected with 1 ng of simian virus 40-Renilla luciferase plasmid as the control for
transfection efﬁciency. 24 h post-transfection cells were incubated with IL-6 (40 ng/ml)
for 20 h. The expression of Fireﬂy and Renilla luciferases was analysed 48 h after
transfection, according to the manufacturer's instructions.3. Results
3.1. Induction of MUC4 expression by IL-6
GP220, MKN45, St23132, St2957 and St3051 gastric cancer cells,
that express the gastric mucin MUC5AC but do not express MUC6
[26], and NUGC-4 gastric cancer cells expressing both, MUC5AC and
MUC6, were subjected to different treatments with IL-6 (20 ng/ml
and 40 ng/ml) to test the induction of the intestinal mucins MUC4
and MUC2.
The selected gastric cancer cell lines do not express MUC4 (Fig. 1A),
and after 20 h IL-6 treatment (20 ng/ml and 40 ng/ml) its expression
was induced.
GP220 andMKN45 cells, which expressedMUC4mRNA at different
levels after 20 h IL-6 stimulation, were selected to further characterise
MUC4 expression induced by IL-6. For this reason, these cells were
treated with IL-6 at different times and doses. In GP220 cells MUC4
mRNA levels increased in a dose- and time-dependent manner. After
10 and 30 min of IL-6 treatment there was not an induction of MUC4
expression (data not shown). MUC4 was detected after 2 h and 20 ng/
ml IL-6 treatment, and the maximum levels of expression were
achieved when cells were incubated with 40 ng/ml IL-6 for 20 h. In
MKN45 cells, the expression ofMUC4was induced at lower levels than
in GP220 cells. MUC4 was detected at 2 h and 20 ng/ml IL-6
stimulation, and the maximum levels were obtained after 5 h IL-6
treatment (Fig. 1B). MUC4 protein expression was analysed by
Western blot and immunoﬂuorescence. GP220 cells were treated
with 20 ng/ml IL-6 or 40 ng/ml IL-6 for 20 h and cell lysates were
subjected toWestern blot. NoMUC4 apomucinwas observed in GP220
untreated cells, but its expression was induced after treating the cells
with IL-6 (Fig. 2A). MUC4 expression was also analysed by immuno-
ﬂuorescence (Fig. 2B), and GP220 untreated cells did not present
MUC4, whereas in GP220 IL-6 treated cells (40 ng/ml IL-6 for 20 or
40 h) MUC4 was detected.
3.2. MUC2 expression is not induced by IL-6
MUC2 expression was also analysed in the six gastric cancer cell
lines after 20 h IL-6 treatment (20 ng/ml and 40 ng/ml). No changes on
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Fig. 5. Blocking of the gp130/STAT3 pathway at the level of the receptor and STAT3 phosphorylation. (A) Quantitative RT-PCR analysis of MUC4 expression in GP220 cells. Non-
incubated or 3 h anti-gp130 antibody incubated cells were treated with 20 ng/ml IL-6 for 2 h or with 40 ng/ml IL-6 for 20 h. Treatments were performed in duplicate. (B) Decreased
activation of STAT3 after blocking the pathwaywith the anti-gp130 antibody.15 μl of total cell lysates were subjected toWestern blotting and STAT3 and p-STAT3 levels were analysed
using speciﬁc antibodies. β-actin (45 kDa) was used as a loading control. (C) MUC4 mRNA levels analysed by quantitative RT-PCR. GP220 cells were incubated with 60 μM AG490, a
speciﬁc inhibitor of STAT activation and 40 ng/ml IL-6 for 2 or 5 h. Experiments were run in duplicate. (D) p-STAT3 levels were analysed by Western blotting from total cell lysates
(15 μl). GP220 cells were incubated with 40 ng/ml IL-6 or with 40 ng/ml IL-6 and 60 μM AG490. β-actin (45 kDa) was used as a loading control.
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St23132 that express MUC2, and no induction on its expression was
observed inMKN45 and NUG-4 cells that do not expressMUC2 (Fig. 3).
3.3. gp130, STAT3 and p-STAT3 levels after IL-6 treatment
The presence of gp130 associated to the cell membrane was
analysedbyﬂowcytometry in untreated and20 h40 ng/ml IL-6 treated
GP220 and MKN45 cells. No differences were detected whenFig. 4. Effect of IL-6 treatment on the activation of the gp130/STAT3 pathway in GP220 and
gp130 in the cell membrane, detected by ﬂowcytometry. (B) Levels of gp130 receptor (130–14
IL-6 and gp130 was detected with an anti-gp130 antibody. β-actin (45 kDa) was used as a load
and 40 ng/ml) for 2, 5, 10 and 20 h in GP220, St2957 and MKN45 cells. 15 μl of total cell lyscomparing control cells and IL-6 treated cells: 22.9% vs. 27.06%, and
49.44% vs. 45.35% positive cells for GP220 and MKN45, respectively
(Fig. 4A). The expression levels of gp130 in other gastric cancer cell
lines were: 56.83% for St2957, 35.24% for St3051 and 51.90% for
St23132.
The transmembrane IL-6 receptor gp130 (130–140 kDa) was
expressed at similar levels in GP220 and MKN45, detected byWestern
blot. After treating the cells with 20 ng/ml or 40 ng/ml IL-6 for 20 h, no
differences in gp130 protein levels were observed (Fig. 4B).MKN45 cells. (A) Percentage of IL-6 treated (40 ng/ml) and untreated cells expressing
0 kDa) in GP220 andMKN45 cells. Cells were treated for 20 hwith 20 ng/ml or 40 ng/ml
ing control. (C) Analysis of STAT3 (79.86 kDa) activation after IL-6 stimulation (20 ng/ml
ates were used for Western blotting. β-actin (45 kDa) was used as a loading control.
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phosphorylated active form p-STAT3, implicated in the IL-6/gp130
pathway, were analysed by Western blot in two cell lines that express
high levels of MUC4 mRNA (GP220 and St2957) and in a cell line
expressing low levels of MUC4 (MKN45) after IL-6 treatment (Fig. 4C).
In GP220 and St2957 untreated cells STAT3 was detected but p-STAT3Fig. 6.MUC4 expression is activated by the binding of p-STAT3 to its promoter. (A) Schemati
sequences of the oligonucleotides used for electrophoretic mobility shift assay (T51 and T63
and Primer set 2) are shown. (B) Nuclear extracts (NE) of GP220 untreated and IL-6 treated (2
were incubated with the radiolabeled probe (T63⁎) or with an excess of cold (T63) or muta
STAT3 antibody or with irrelevant immunoglobulins (IgG). (C) MUC4 promoter binding to p-S
and IL-6 treated (2 h and 20 ng/ml) cells. 1) Enrichment levels in p-STAT3 binding toMUC4 pr
MUC4 promoter represented as relative occupancy (percent of input). Results were obtaine
activity in untreated and IL-6 treated cells was analysed by reporter luciferase assays. The valu
of two independent experiments are shown.was not present. p-STAT3 was detected after 10 and 30 min IL-6
treatment (Supplementary material). In GP220 cells, maximum levels
of p-STAT3 were observed after 2 h of IL-6 treatment. STAT3 activation
was IL-6 dose-dependent, and higher levels of p-STAT3 were detected
when IL-6 concentration (40 ng/ml) was increased. p-STAT3 expres-
sion decreased in a time-dependent fashion and after 20 h treatmentc representation of MUC4 promoter. The two putative STAT-binding sites, as well as the
), and the primers used for chromatin immunoprecipitation experiments (Primer set 1
0 ng/ml for 2 h) cells were subjected to electrophoretic mobility shift assays. The extracts
ted (T63mut) probe. For supershift assays nuclear extracts were incubated with anti-p-
TAT3 analysed by chromatin immunoprecipitation. p-STAT3 binding of GP220 untreated
omoter normalized to an irrelevant promoter. 2) Presence of sequences corresponding to
d using Primer set 2. (D) MUC4 wild type (2150) and MUC4 mutated (3008) promoter
es obtained in cells transfected with the empty vector were referred as to 1. Means±S.D.
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treatment and its levels did not change with time.
In MKN45 cells STAT3 was constitutively active, and IL-6
treatment at different times (2, 5, 10 and 20 h) and doses (20 and
40 ng/ml) did not induce remarkable differences in p-STAT3
expression levels.
3.4. Anti-gp130 and AG490 incubation decrease STAT3 activation and
MUC4 expression
To determine the direct involvement of the IL-6/gp130/STAT3
pathway in regulating MUC4 transcription, GP220 and St2957 cells
were selected because they do not express p-STAT3 constitutively.
This pathway was blocked at two different levels: at the level of the
gp130 receptor and at the level of STAT3 activation.
To block the IL-6 binding to its receptor, GP220 and St2957 cells
were incubated with a speciﬁc antibody against the transmembrane
type I cytokine receptor β-subunit gp130 for 3 h previously to IL-6
stimulation (20 ng/ml and 40 ng/ml), and MUC4 mRNA levels were
analysed by quantitative RT-PCR after 2 and 20 h. In GP220 cells
incubated with the antibody lower levels of MUC4 mRNA were
detected (Fig. 5A). The same results were obtained with St2957 cells
(data not shown). Regarding STAT3 activation, decreased levels of p-
STAT3 were observed in GP220 cells (Fig. 5B) and St2957 cells (data
not shown) incubated with the antibody.
To block STAT3 activation, cells were incubated with the potent
inhibitor of the Jak tyrosine kinase family AG490 [27]. When GP220
cells were treated with a combination of 60 μM AG490 and 40 ng/ml
IL-6 for 2 or 5 h, therewas a detectable decrease in MUC4mRNA levels
(Fig. 5C). p-STAT3 protein levels were also analysed after 2 h AG490-
IL6 treatment. A signiﬁcant decrease in STAT3 activationwas observed
in AG490 GP220 treated cells (Fig. 5D). In MKN45 untreated cells that
express p-STAT3 constitutively the same effect of AG490 was detected
(Supplementary material).
3.5. p-STAT3 activates MUC4 expression through its binding to MUC4
promoter
To assess the binding of the active form of STAT3 to MUC4
promoter, which contains two putative STAT-binding sites (Fig. 6A),
electrophoretic mobility shift assays, chromatin immunoprecipitation
and luciferase reporter experiments were done.
EMSA assays were performed using two different radiolabeled
probes (T63⁎ and T51⁎), including the two STAT-binding sites in
MUC4 promoter (Fig. 6A). No retardation complexes were detected
when incubating nuclear extracts from GP220 untreated and GP220
IL-6 treated cells (20 ng/ml for 2 h) with T51⁎ probe (data not
shown). Protein–DNA interaction was observed when the extracts
were incubated with T63⁎ probe (Fig. 6B). This interaction
disappeared when samples were incubated with an excess of cold
unlabeled oligonucleotides or with the mutated T63 probe. As
expected, a supershift band was only detected in GP220 IL-6 treated
cells.
In vivo binding of p-STAT3 to MUC4 promoter was conﬁrmed by
ChIP experiments. Two different sets of speciﬁc primers, to include
each of the two STAT-binding sites in MUC4 promoter, were designed
(Fig. 6A). No binding was detected when Primer set 1 was used for
quantitative PCR. In contrast, a three-fold increase in p-STAT3 binding
to MUC4 promoter was observed in GP220 cells treated with 20 ng/ml
of IL-6 for 2 h, when using Primer set 2 (Fig. 6C).
To conﬁrm that T63 STAT-binding site of MUC4 promoter is
required for its activation after IL-6 treatment, reporter luciferase
assays were performed. GP220 cells transfected with the MUC4 wild
type promoter (2150) showed increased promoter activity after IL-6
stimulation, that was not detected in IL-6 treated cells transfected
with the T63 mutant construct (Fig. 6D).Together, these data demonstrate that the active form of STAT3 (p-
STAT3) can regulate MUC4 transcription through its direct binding to
MUC4 promoter.
4. Discussion
The activation of intestinal genes in the sequential process that
leads to gastric cancer has been well reported, but the mechanisms
involved in their activation remain not fully identiﬁed. The intestinal
mucin genes, MUC2 and MUC4, have been detected in gastric tumors
and in the early stages of the gastric carcinogenesis process [9,10,28].
The activation of MUC2 has been associated to the intestinal speciﬁc
transcription factors CDX1 and CDX2, that are co-expressed with
MUC2 in intestinal metaplasia and gastric carcinomas [29,30]. More-
over, the ectopic expression of Cdx2 in the gastric mucosa induces
intestinal metaplasia in mice [31], suggesting that MUC2 can be
activated by CDX2 in gastric cells [25]. Our observation that no
changes in MUC2 expression were induced in the gastric cancer cell
lines treated with IL-6 is consistent with the fact that no STAT boxes
have been described in the MUC2 promoter [32].
No data regarding the activation of MUC4 have been reported in
gastric models. However, the induction of MUC4 expression by IFN-
γ through STAT1 up-regulation in pancreatic cancer cells by the
binding of STAT1 to various γ-interferon-activated sequences (GAS)
in the MUC4 promoter has been recently described [33]. Here, we
report the activation of MUC4 expression by the pro-inﬂammatory
cytokine IL-6 through the gp130/STAT3 pathway. Two putative STAT-
binding sites in the 3′-end of MUC4 5′-UTR have been described
[23], indicating a role for STAT transcription factors in the
transcriptional regulation of MUC4. By EMSA, ChIP and reporter
luciferase assays, we demonstrate that p-STAT3 can bind directly to
one of these two sites, located at the promoter region 3582–3604
(NCBI Sequence), modulating MUC4 expression after IL-6 stimula-
tion in GP220 gastric cancer cells.
The role of MUC4 in the neoplastic transformation of the gastric
mucosa must be associated to signalling pathways controlling cell
growth through the trafﬁc andmembrane localization of speciﬁc growth
factor receptors [34], but the implication of inﬂammatory cytokines in
the activation of speciﬁc intestinalmarkers during the sequential process
of stomach carcinogenesis has not been carefully analysed. In gastric
carcinoma increased serum levels of IL-6 have been correlated with the
disease status [35], and in AGS gastric cancer cells, IL-6 promotes cell
motility and invasiveness by the activation of the Src/Rho/ROCK
signalling pathway, suggesting an important role in tumor progression
in gastric cancer [36]. High levels of IL-6 results in the persistent
activation of STAT3 that is present in several mouse and human
malignancies suggesting a relation between hyperactivated STAT3 and
tumorigenesis [37]. In a mouse model of gp130ΔSTAT that abolishes the
STAT1/3 signalling pathway, it has been suggested that themaintenance
of the integrity of the gastric mucosa depends on the relation between
the STAT1/3 and SHP2-Ras-ERK pathways activated through the binding
of IL-6 to the gp130 receptor [38]. Moreover, hyperactivation of Stat3 in
gp130 mutant mice promotes tumor initiation and growth, and
contributes to inﬂammation, angiogenesis and cell proliferation in
gastric epithelium [39,40]. In human cancer, it has been suggested that
STAT factors contribute to tumorigenesis by their implication in
angiogenesis and apoptosis through the growth factor signalling [41].
In gastric cancer, theangiogenic phenotype and theVEGFoverexpression
correlated with elevated STAT3 expression, and abnormally activated
STAT3 has been postulated as a marker for poor prognosis [42].
Moreover, in a recent report it has been described that human gastric
cancer progression is accompanied by increased gp-130 mediated
cytokine signalling [43].
The activation of MUC4 by the direct binding of STAT3 to the STAT-
binding sites in theMUC4 promoter after IL-6 stimulation has not been
previously reported. This novel mechanism suggests that the
1736 R. Mejías-Luque et al. / Biochimica et Biophysica Acta 1783 (2008) 1728–1736inﬂammatory response detected in the stomach mucosa may play a
role in the activation of genes implicated in gastric carcinogenesis.
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